Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Request a Policy / Feedback
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.31
    OpenPayerPolicy UpdatesPharmacy & Specialty DrugsViva Health Xeomin prior auth & coverage | OpenPay…
    Ask Trek AI about this page
    CurrentViva HealthPolicy IC-0241

    Xeomin (incobotulinumtoxinA) coverage and authorization

    Customize your policy alerts

    Sign up for Viva Health Policy IC-0241 alerts

    Get alerted when Policy IC-0241 changes without checking for updates manually.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    Defines prior authorization, dosing limits, indications, and renewal criteria for Xeomin (incobotulinumtoxinA) for multiple intramuscular/intradetrusor/intradermal/intraglandular indications for Viva Health members.

    Policy Summary
    PayerViva Health
    PolicyXeomin (incobotulinumtoxinA) coverage and authorization
    Policy CodePolicy IC-0241
    Change TypeNo material change
    Effective DateJul 1, 2026
    Last ReviewJul 1, 2026
    Next Review DateJul 1, 2026
    Key ActionObtain prior authorization: initial approvals valid 180 days; renewals valid 365 days and member must meet age, indication, dosing, and documentation requirements.
    SourceLink
    POLICY UPDATE CHANGES

    No material clinical or coverage changes in this revision.

    180 daysinitial prior authorization validity
    365 daysrenewal prior authorization validity
    400max units (most indications)
    500ventral hernia max units

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    ≥18
    minimum age (general)
    J0588HCPCS code

    Coverage Criteria

    Initial Approval Universal Criteria

    Covered when ALL of the following are met:

    Universal: Member is at least 18 years of age (unless otherwise specified); member does NOT have any FDA‑labeled contraindications to the requested agent (e.g., hypersensitivity to any botulinum toxin product or any excipient, active infection at the proposed injection site); member is not on concurrent treatment with another botulinum toxin.

    Prior authorization validity: initial approvals valid for 180 days (see authorization section).

    Cervical Dystonia

    Covered for cervical dystonia when ALL of the following are met:

    Cervical Dystonia: Member has a history of recurrent involuntary contraction of one or more muscles in the neck and upper shoulders; AND member has sustained head tilt OR abnormal posturing with limited range of motion in the neck.

    Marked † indicates FDA‑approved indication.

    Blepharospasm and Spasticity

    Covered when ANY of the following applicable spastic conditions are present:

    Blepharospasm/Spastic Conditions: Member has blepharospasm; OR adult upper limb spasticity; OR pediatric upper limb spasticity in members aged 2 to 17 years (excluding spasticity caused by cerebral palsy).

    Prophylaxis for Chronic Migraines

    Covered when ALL of the following are met:

    Chronic Migraine: Physician has assessed baseline disease severity using an objective measure/tool (e.g., HIT‑6, monthly headache day count [MHD], MIDAS, MPFID); AND member is utilizing prophylactic intervention modalities (e.g., trigger management, pharmacotherapy, behavioral therapy, neuromodulation, physical therapy); AND other causes of headache have been ruled out; AND member has a diagnosis of chronic migraine defined as ≥15 headache days per month for >3 months; AND on ≥8 days/month for >3 months headaches have migraine features (relieved by triptans/ergots OR present with aura OR have provider‑determined migraine characteristics).

    Compendia‑referenced indication (‡).

    Incontinence due to Neurogenic Detrusor Overactivity

    Covered when ALL of the following are met:

    Neurogenic Detrusor Overactivity: Member has detrusor overactivity associated with a neurologic condition confirmed by urodynamic testing; AND member has failed a ≥1 month trial of two medications from either the antimuscarinic class (e.g., darifenacin, fesoterodine, oxybutynin, solifenacin, tolterodine, trospium) or the beta‑adrenergic class (e.g., mirabegron, vibegron).

    Urodynamic confirmation required.

    Overactive Bladder (OAB)

    Covered when ALL of the following are met:

    Overactive Bladder: Member has symptoms of urge urinary incontinence, urgency, and frequency; AND member has failed a ≥1 month trial of two medications from either the antimuscarinic class (e.g., darifenacin, fesoterodine, oxybutynin, solifenacin, tolterodine, trospium) or the beta‑adrenergic class (e.g., mirabegron, vibegron).

    Compendia‑recommended context (‡).

    Severe Primary Axillary Hyperhidrosis

    Covered when ALL of the following are met:

    Axillary Hyperhidrosis: Member has tried and failed a ≥1 month trial of a topical agent (e.g., 20% aluminum chloride, glycopyrronium, aluminum zirconium trichlorohydrate, sofpironium, etc.); AND member has either a history of medical complications (e.g., skin infections) or significant functional impairment OR a substantial burden impacting activities of daily living (e.g., impairment in work performance, frequent clothing changes, social/relationship difficulty).

    Chronic Sialorrhea

    Covered when ALL of the following are met:

    Chronic Sialorrhea: Member has troublesome sialorrhea for at least 3 months; AND member has Parkinson disease, atypical Parkinsonism, stroke, or traumatic brain injury OR severe developmental delay OR cerebral palsy/other genetic or congenital disorders/traumatic brain injury; AND member is at least 2 years of age.

    FDA‑approved and compendia‑recommended contexts indicated where specified.

    Ventral Hernia (preoperative)

    Covered when ALL of the following are met:

    Ventral Hernia (preoperative): Member has a large ventral hernia with loss of domain or a contaminated ventral hernia; AND Xeomin is being used preoperatively in members scheduled for abdominal wall reconstruction (AWR).

    Prior authorization validity may NOT be renewed for the ventral hernia indication; ventral hernia dosing/maximum differs (see dosing section).

    Indication-specific coverage criteria

    Covered when ALL of the following are met for each indication as specified below

    Upper Limb Spasticity: Significant decrease in tone and/or resistance of affected areas documented by a validated measuring tool (e.g., Ashworth Scale, Physician Global Assessment, CGI).objective decrease on validated tool

    Follow pediatric/adult dosing limits in dosing section (adults up to 400 units total; pediatric weight‑based limits apply).

    Severe Primary Axillary Hyperhidrosis (objective outcomes): Significant reduction in spontaneous axillary sweat production; AND significant improvement in activities of daily living (ADL).objective sweat reduction and ADL improvement

    Dose example: 50 units intradermally per axilla every 16 weeks.

    Prophylaxis for Chronic Migraine (objective outcomes): Significant decrease in number, frequency, and/or intensity of headaches compared to baseline on an objective measure/tool (e.g., HIT‑6, MHD, MIDAS, MPFID); AND improvement in function; AND continued use of prophylactic intervention modalities.

    Prior authorization for Xeomin used preoperatively for ventral hernia is limited: initial prior authorizations follow standard rules but, per policy, prior authorization validity may NOT be renewed for the ventral hernia indication. Providers should plan one-time authorization and document the preoperative use for abdominal wall reconstruction as specified in the ventral hernia criteria.

    Units of Xeomin (incobotulinumtoxinA) are specific to its preparation and assay method and are not interchangeable with units of other botulinum toxin products. Do not convert or substitute unit dosing between products when documenting or billing; dosing must use Xeomin units as stated in this policy.

    Medicare Part B rules may supersede this policy when applicable. National Coverage Determinations (NCDs), Local Coverage Determinations (LCDs), and Local Coverage Articles (LCAs) for CMS/Medicare Part B may apply and take precedence; providers should consult the Medicare Coverage Database and applicable contractor guidance for Part B billing and coverage requirements.

    The policy specifies a maximum cumulative dose of 400 Units per treatment session for most indications. Coverage beyond this 400 Unit per-session limit is not supported, except where the policy explicitly notes an exception for the ventral hernia preoperative indication (see ventral hernia dosing guidance).

    Coding and Billing

    Max Units (per dose and over time)HCPCS
    HCPCS UnitIndication-specific maximum billable units per dose and per # days as listed (e.g., Cervical Dystonia 200 units per dose / 84 days; Blepharospasm 100 units per dose / 84 days; Ventral Hernia 500 units per dose / N/A days; see policy for full per‑indication table).
    Covered HCPCS CodesHCPCSCovered
    J0588Injection, incobotulinumtoxinA, 1 unit; 1 billable unit = 1 unit
    NDCsNDC
    00259-1605-xxXeomin 50 unit powder for injection; single-dose vial
    00259-1610-xxXeomin 100 unit powder for injection; single-dose vial
    00259-1620-xxXeomin 200 unit powder for injection; single-dose vial
    Covered ICD-10 Diagnosis Codes (Appendix 1, partial)ICD-10Covered
    G24.3Spasmodic torticollis
    G24.5Blepharospasm
    G25.89Other specified extrapyramidal and movement disorders
    G35.ARelapsing-remitting multiple sclerosis
    G35.B0Primary progressive multiple sclerosis, unspecified
    G35.B1Active primary progressive multiple sclerosis
    G35.B2Non-active primary progressive multiple sclerosis
    G35.C0Secondary progressive multiple sclerosis, unspecified
    G35.C1Active secondary progressive multiple sclerosis
    G35.C2Non-active secondary progressive multiple sclerosis
    1–10 of 103
    1/11
    Referenced LCD/LCA document identifiersmixed
    A59707Local Coverage Article: Billing and Coding: Botulinum Toxin Injections (NGS reference)
    A57186Local Coverage Article: Billing and Coding: Botulinum Toxin Injections (Noridian)
    A59809Local Coverage Article: Billing and Coding: Botulinum Toxin Injections (WPS)
    A59726Local Coverage Article: Billing and Coding: Botulinum Toxins Injections (CGS)
    A57185Local Coverage Article: Billing and Coding: Botulinum Toxin Injections (Noridian alternate)
    A59714Local Coverage Article: Billing and Coding: Botulinum Toxin Injections (Palmetto GBA)
    A57715Local Coverage Article: Billing and Coding: Botulinum Toxins (First Coast)
    A58423Local Coverage Article: Billing and Coding: Botulinum Toxins (Novitas)
    Chronic migraine diagnostic threshold — diagnostic thresholds (e.g., headache days per month)
    Chronic migraine diagnostic threshold15 or more headache days per month for >3 months, with at least 8 days/month having migraine features (e.g., relieved by triptans/ergots, aura, or migraine characteristics) for >3 months
    Baseline severity documentationPhysician must assess baseline disease severity using an objective tool (e.g., HIT-6, monthly headache day [MHD], MIDAS, MPFID)
    Concurrent prophylactic modalitiesMember should be utilizing prophylactic interventions (behavioral therapy, pharmacotherapy, neuromodulation, trigger management, physical therapy) during Xeomin therapy
    Dose limits and intervals — per-indication maximums and minimum intervals (e.g., no sooner than every 12 weeks for most indications)
    General repeat interval (most indications)

    Provider Actions and Documentation Requirements

    Prior Authorization

    Prior authorization required; initial 180 days, renewals 365 days

    Prior authorization is required for Xeomin. Initial approvals are valid for 180 days (6 months); subsequent renewals may be authorized every 12 months (365 days) unless otherwise specified. Members must meet age and universal initial criteria (e.g., age ≥18 unless otherwise specified, no FDA‑labeled contraindications, and not receiving concurrent botulinum toxin therapy).

    • Initial PA: 180 days (6 months)
    • Renewal PA: 365 days (12 months)
    • Member must meet age and universal initial criteria (see policy)
    Billing Rule

    PA applies to administration billed with HCPCS J0588; NDCs/vial sizes noted

    Initial Therapy Criteria

    Initial Therapy Criteria

    Initial approval provided when universal and indication-specific criteria are met:

    Initial Therapy: Member meets the universal initial approval criteria (age, absence of contraindications, no concurrent botulinum toxin) AND meets the indication‑specific criteria for the requested diagnosis as listed in the policy.

    Initial prior authorization validity is 180 days; localization of injection sites with EMG/nerve stimulation/ultrasound is recommended.

    Initial therapy dosing examples

    Initial dosing where specified

    Cervical Dystonia initial dose: Recommended initial total dose for cervical dystonia is 120 units divided among affected muscles every 12 weeks or longer; adjust per muscle size/response and use localization guidance.120 units initial

    Renewal and Repeat Dosing

    Renewal Criteria

    Renewal allowed when the following are met:

    Renewal Requirements: Member continues to meet the universal and indication‑specific criteria; duration of prior authorization has not been exceeded; absence of unacceptable toxicity from the drug (e.g., signs of toxin spread, serious hypersensitivity, corneal exposure/ulceration, ectropion); AND disease response is evident per indication‑specific objective measures.

    Renewals are valid for 365 days when criteria met.

    Repeat dosing

    Continuation/repeat dosing requirements per indication

    General repeat interval: Most indications: repeat treatment no sooner than every 12 weeks; sialorrhea and hyperhidrosis: repeat no sooner than every 16 weeks unless otherwise specified.>=12 weeks for most; >=16 weeks for sialorrhea/hyperhidrosis

    Maximum cumulative dose per treatment session: 400 Units for most indications (ventral hernia exception up to 500 Units).

    Step Therapy and Prior Conservative Treatments

    IndicationRequired prior conservative therapy (documentation of failure required before authorization)Notes / duration
    Incontinence due to Neurogenic Detrusor Overactivity
    Member has failed a ≥1 month trial of two medications from either the antimuscarinic (e.g., darifenacin, fesoterodine, oxybutynin, solifenacin, tolterodine, trospium) or beta-adrenergic (e.g., mirabegron, vibegron) classes (documentation required)
    Urodynamic testing confirming detrusor overactivity associated with a neurologic condition is required; trials must be ≥1 month each
    IndicationConcurrent/prophylactic modalities expectedStep therapy status / requirement
    Member continues to utilize prophylactic intervention modalities (e.g., trigger avoidance, pharmacotherapy, behavioral therapy, neuromodulation, physical therapy)
    Continued use of other prophylactic modalities is expected alongside Xeomin; this is not framed as a strict prior-step failure but as concurrent management

    Quantity Limits

    Xeomin (incobotulinumtoxinA) — Indication-specific unit limits
    Cervical DystoniaMaximum per dose: 200 units (per 84 days).
    BlepharospasmMaximum per dose: 100 units (per 84 days).
    Ventral Hernia (preoperative)Maximum per dose: 500 units (injected 2–4 weeks prior to abdominal wall reconstruction).
    Upper Limb Spasticity (adult)Up to 400 units total per session (per dosing guidance).
    Xeomin (incobotulinumtoxinA) — Maximum cumulative dose per treatment session
    Maximum cumulative dose (most indications)400 Units per treatment session (recommended maximum cumulative dose for any indication, unless used for ventral hernia).

    Site of Care and Procedural Guidance

    Documentation Required

    Use EMG, nerve stimulation, or ultrasound to localize involved muscles for injections

    When injecting muscles for spasticity or other muscular indications, localization of involved muscles with electromyographic (EMG) guidance, nerve stimulation, or ultrasound is recommended and should be used per the dosing/administration guidance.

    • Localization methods: EMG guidance, nerve stimulation, or ultrasound

    Background

    Xeomin (incobotulinumtoxinA) is a botulinum toxin type A product administered via intramuscular, intradetrusor, intradermal, or intraglandular injection for a range of neurologic and autonomic conditions. The policy lists both FDA‑approved and compendia‑recommended uses and provides indication‑specific dosing, documentation, and authorization requirements. Localization techniques such as EMG, ultrasound, or nerve stimulation are recommended to guide injections and optimize targeting.

    Definitions and Measurement Tools

    FDA approved (†) and Compendia recommended (‡) — Policy annotation conventions
    FDA and compendia annotationPolicy annotates indications with † for FDA-approved and ‡ for compendia-recommended uses.
    Example markingVentral Hernia is marked with ‡ (compendia recommended) in the policy text; FDA-approved indications are annotated with †.
    Usage in textAnnotation symbols appear alongside indication headings to indicate regulatory or compendia status.
    Validated measurement tools
    Ashworth Scale (spasticity)Used to document decrease in tone/resistance for upper limb spasticity outcomes.
    Headache measuresHIT-6, monthly headache day (MHD), MIDAS, MPFID used to document baseline and response for chronic migraine.
    Policy Summary
    PayerViva Health
    PolicyXeomin (incobotulinumtoxinA) coverage and authorization
    Policy CodePolicy IC-0241
    Change TypeNo material change
    Effective DateJul 1, 2026
    Last ReviewJul 1, 2026
    Next Review DateJul 1, 2026
    Key ActionObtain prior authorization: initial approvals valid 180 days; renewals valid 365 days and member must meet age, indication, dosing, and documentation requirements.
    SourceLink
    On This Page
    Coverage CriteriaCoding and BillingProvider Actions and Documentation RequirementsInitial Therapy CriteriaRenewal and Repeat DosingStep Therapy and Prior Conservative TreatmentsQuantity LimitsSite of Care and Procedural GuidanceBackgroundDefinitions and Measurement Tools
    significant decrease in headache metrics vs baseline

    Dose example: up to 200 units every 12 weeks.

    Neurogenic Detrusor Overactivity (objective outcomes): Significant improvements in weekly frequency of incontinence episodes; AND periodic assessment of post‑void residual (PVR) as medically appropriate.reduced weekly incontinence episodes; monitored PVR

    Dose example: up to 200 units per treatment every 12 weeks.

    Overactive Bladder (OAB) (objective outcomes): Significant improvement in daily frequency of urinary incontinence or micturition episodes and/or volume voided per micturition; AND periodic assessment of PVR as medically appropriate.improved urinary frequency/volume; monitored PVR

    Dose example: up to 100 units per treatment every 12 weeks.

    Chronic Sialorrhea (objective outcomes): Significant decrease in saliva production documented.objective decrease in saliva production

    Adult dosing example: 30 units per parotid and 20 units per submandibular gland per side (total 100 units); pediatric weight‑based dosing and repeat interval no sooner than every 16 weeks.

    Repeat no sooner than every 12 weeks
    Sialorrhea and hyperhidrosis repeat intervalRepeat no sooner than every 16 weeks (adult and pediatric dosing as specified)
    Maximum cumulative dose per treatment sessionRecommended maximum cumulative dose 400 Units per treatment session (ventral hernia exception: up to 500 Units)
    Indication-specific maximumsChronic migraine up to 200 units; Neurogenic detrusor overactivity up to 200 units; Overactive bladder up to 100 units; Cervical dystonia initial 120 units (max per session per dosing guidance), Blepharospasm initial 50 units (naïve) with subsequent ≤100 units
    NQTL considerations — indication/safety/cost checklist items
    Indication considered?Yes — indication was a factor in requiring prior authorization
    Safety and efficacy considered?Yes — safety and efficacy were considered in PA design
    Potential for misuse/abuseNo — potential for misuse/abuse was not a priority for PA
    Cost considered?Yes — drug cost was considered in applying PA

    Prior authorization applies to administration of incobotulinumtoxinA billed with HCPCS code J0588 (Injection, incobotulinumtoxinA, 1 unit). NDCs and available single‑dose vial sizes (50, 100, 200 units) are listed for reference and billing.

    • HCPCS: J0588 — Injection, incobotulinumtoxinA, 1 unit
    • NDCs: 00259-1605-xx (50 units); 00259-1610-xx (100 units); 00259-1620-xx (200 units)
    Prior Authorization

    PA may be used based on indication, safety/efficacy, and cost (NQTL)

    Prior authorization may be applied using the NQTL factor checklist — consideration is given based on the clinical indication, safety and efficacy evidence, and drug cost. These NQTL factors support use of PA for Xeomin.

    • NQTL conclusions: Indication = Yes (consider PA); Safety/efficacy = Yes (consider PA); Cost = Yes (consider PA)
    Step Therapy

    Document failure of specified conservative therapies prior to authorization

    For bladder indications (neurogenic detrusor overactivity and OAB) and for severe primary axillary hyperhidrosis, prior authorization requires documentation of failure of specified conservative therapies before approval.

    • Neurogenic detrusor overactivity: failed ≥1 month trial of two medications from antimuscarinic or beta‑adrenergic classes
    • Overactive bladder: failed ≥1 month trial of two medications from antimuscarinic or beta‑adrenergic classes
    • Axillary hyperhidrosis: failed ≥1 month trial of a topical agent (e.g., 20% aluminum chloride, glycopyrronium, etc.)
    Step Therapy

    Continue other prophylactic modalities alongside Xeomin for chronic migraine

    For chronic migraine prophylaxis, members are expected to continue other prophylactic modalities (behavioral therapy, pharmacotherapy, neuromodulation, trigger management, physical therapy) in conjunction with Xeomin rather than substituting them.

    • Continue prophylactic interventions such as avoiding triggers, pharmacotherapy, behavioral therapy, neuromodulation, and physical therapy
    Step Therapy

    No additional explicit step therapy requirements specified

    No explicit step‑therapy (forced prior‑step) sequence is specified in this policy excerpt; the document does not present additional mandatory step requirements beyond the conservative therapy trials noted for certain indications.

    Documentation Required

    Document baseline disease severity with objective measure for chronic migraine

    For chronic migraine prophylaxis, the physician must document baseline disease severity using an objective validated tool (e.g., HIT‑6, monthly headache day counts, MIDAS, MPFID) as part of the prior authorization submission.

    • Examples: Headache Impact Test (HIT‑6); monthly headache days (MHD); MIDAS; MPFID
    Documentation Required

    Urodynamic testing confirming neurogenic detrusor overactivity required

    For neurogenic detrusor overactivity, prior authorization requires documentation of urodynamic testing that confirms detrusor overactivity associated with a neurologic condition (e.g., spinal cord injury, multiple sclerosis).

    • Urodynamic testing confirming detrusor overactivity associated with a neurologic condition is required
    Documentation Required

    Document objective measures and functional improvement per indication

    Providers must document objective, indication‑specific clinical response to support renewal and continuation. Examples include decreased tone on the Ashworth Scale for spasticity, reduction in monthly headache days or validated headache disability scores for migraine, and reduced incontinence episodes with periodic PVR assessment for bladder indications.

    • Spasticity: validated tool such as Ashworth Scale or CGI showing decreased tone/resistance
    • Chronic migraine: objective decrease in headache metrics (HIT‑6, MHD, MIDAS) and functional improvement
    • Bladder indications: reduced incontinence episodes and periodic post‑void residual (PVR) assessments
    • Hyperhidrosis/sialorrhea: documented reduction in sweat or saliva production and ADL improvement as applicable
    Note

    PA consideration guided by NQTL factors (indication, safety/efficacy, cost)

    Prior authorization may be considered based on the NQTL checklist factors; document the clinical indication, safety/efficacy rationale, and any cost considerations as relevant to the request.

    Denial Risk

    Check for FDA‑labeled contraindications and concurrent botulinum toxin therapy

    Requests may be denied or require additional documentation when members have FDA‑labeled contraindications such as hypersensitivity to any botulinum toxin product or active infection at the proposed injection site, or when the member is receiving concurrent treatment with another botulinum toxin.

    • Contraindications: hypersensitivity to any botulinum toxin product or excipient; active infection at proposed injection site
    • Concurrent botulinum toxin therapy: documentation that member is not receiving another botulinum toxin is required
    Denial Risk

    Absence of documented objective improvement may prevent renewal

    Lack of documented objective improvement on validated measurement tools (e.g., Ashworth Scale for spasticity; HIT‑6, MHD, MIDAS for migraine) or absence of documentation of functional improvement may prevent renewal and lead to denial.

    • Validated tools cited: Ashworth Scale, HIT‑6, monthly headache days (MHD), MIDAS
    Billing Rule

    Claims using primary G/M codes require a secondary G or I diagnosis code

    Claims billed with primary G and M codes must include the required secondary G or I diagnosis code to be payable; failure to include the secondary code risks denial or non‑payment.

    • Ensure primary G/M procedure claims include the required secondary G or I diagnosis code to avoid denial
    Blepharospasm initial dose: Treatment‑naïve members: recommended initial dose 50 units (25 units per eye). Subsequent doses in previously treated members should not exceed 100 units per session (50 units per eye), every 12 weeks or longer.50 units initial naïve; ≤100 units subsequent

    Tailor dose and frequency to individual response.

    Chronic Migraine dosing example: Up to 200 units divided among affected muscles every 12 weeks.≤200 units every 12 weeks
    Neurogenic Detrusor Overactivity dosing example: Up to 200 units per treatment divided among affected sites every 12 weeks.≤200 units every 12 weeks
    Overactive Bladder dosing example: Up to 100 units per treatment divided among affected muscles every 12 weeks.≤100 units every 12 weeks
    Severe Primary Axillary Hyperhidrosis dosing example: 50 units intradermally per axilla every 16 weeks.50 units per axilla every ≥16 weeks
    Chronic Sialorrhea dosing example: Adults: 30 units per parotid gland and 20 units per submandibular gland per side (total 100 units per session); pediatric weight‑based dosing specified; repeat no sooner than every 16 weeks.total 100 units adults; pediatric per weight chart
    Ventral Hernia dosing example: Ventral hernia: 500 units divided among abdominal muscles, injected 2–4 weeks prior to abdominal wall reconstruction.500 units for ventral hernia

    Ventral hernia is an exception to the 400‑unit cumulative maximum and prior authorization renewals are not permitted for this indication.

    Chronic migraine session maxUp to 200 units per treatment session every 12 weeks.
    OAB session maxUp to 100 units per treatment session every 12 weeks.
    Incontinence measuresWeekly incontinence episode frequency and periodic post-void residual (PVR) assessment for neurogenic detrusor overactivity and OAB.
    Hyperhidrosis & sialorrheaValidated measures of spontaneous axillary sweat reduction and decrease in saliva production with functional/ADL improvement documented.